First patient randomised as study advances novel pan phosphate transporter inhibitor

Move sharpens Mission’s focus on CNS pipeline as renal specialist takes AKI asset forward

Long‑term follow‑up reinforces momentum toward registration‑enabling trial

Company to showcase INSTI-powered innovation across treatment and PrEP

Combined company to advance biologics for immunologically‑driven disorders

Partnership to support first‑in‑human trial of EPY201 in epilepsy

Guidance expands treatment options for patients

Breakwater data show significant survival gains over standard chemotherapy

At‑home autoinjector option offers new flexibility for patients and care partners

Non-hormonal option to be made available for patients unsuitable for HRT